Document is current
Any future updates will be listed below
-
Authors
Paczkowska, Julia
Tang, Ming
Wright, Kyle T.
Song, Li
Luu, Kelsey
Shanmugam, Vignesh
Welsh, Emma L. https://orcid.org/0009-0009-7345-5106
Weirather, Jason L.
Besson, Naomi https://orcid.org/0009-0008-3548-913X
Olszewski, Harrison
Porter, Billie A.
Pfaff, Kathleen L.
Redd, Robert A. https://orcid.org/0000-0002-1329-5288
Cader, Fathima Zumla
Mandato, Elisa
Ouyang, Jing
Calabretta, Eleonora
Bai, Gali
Lawton, Lee N.
Armand, Philippe https://orcid.org/0000-0001-6098-1603
Rodig, Scott J.
Liu, Xiaole Shirley https://orcid.org/0000-0003-4736-7339
Shipp, Margaret A. https://orcid.org/0000-0002-3949-6897
- License Information
-
More Information
Article History
Received: 7 February 2024
Accepted: 11 November 2024
First Online: 30 December 2024
Competing interests
: M.T. is a full-time employee of Astra Zeneca. K.L. is a full-time employee of PathAI. F.Z.C. is a full-time employee of AstraZeneca. J.O. is a full-time employee of Bristol Myers Squibb. P.A. consults for Merck, Bristol Myers Squibb, A.D.C. Therapeutics, GenMab, Enterome, Genentech/Roche, ATB Therapeutics, Foresight Diagnostics, AstraZeneca, MSD, Tessa Therapeutics, Regeneron, Xencor, and receives institutional research funding from Merck, Bristol Myers Squibb, Genentech/Roche, KITE/Gilead, Adaptive Biotechnologies, IGM, AstraZeneca, MSD, Aamed Therapeutics and honoraria from Merck. S.J.R. receives institutional research funding from Bristol Myers Squibb, KITE/Gilead and is an advisory board member of Immunitas Therapeutics. X.S.L. is the founder and CEO of GV20 Therapeutics, LLC. M.A.S. has received research funding from Bristol Myers Squibb, AstraZeneca, Bayer Abbvie, Genentech and Novartis and has served on advisory boards for Bristol Myers Squibb and AstraZeneca. The remaining authors declare no competing financial interests. No authors have non-financial competing interests.
